Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998 | 0.75 | HTR2C (0.46) | HTR2CGAAPNMTCD44MAOB | |
| SCHEMBL5254989 | 0.73 | PARP10 (0.47) | MEN1KMT2AKDM1AALDH1A1GAA | |
| SCHEMBL6307312 | 0.70 | HTR2C (0.64) | HTR2CMEN1KMT2APNMTCD44 | |
| SCHEMBL9819924 | 0.69 | MEN1 (0.39) | MEN1KMT2ATRPA1CA1CA2 | |
| SCHEMBL5844898 | 0.69 | DRD2 (0.48) | KDM1AMAOBCA1CA2 | |
| SCHEMBL7137780 | 0.69 | PNMT (0.47) | HTR2CKDM1APNMTAHR | |
| SCHEMBL10399612 | 0.69 | HTR2C (0.45) | HTR2CMEN1KMT2APOLBMAOB | |
| SCHEMBL6635609 | 0.68 | KDM4E (0.45) | MEN1KMT2AALDH1A1GAAHPGD | |
| SCHEMBL6948172 | 0.68 | MAOA (0.45) | HTR2CMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2504099 | 0.67 | MEN1 (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150222-A1 | IONIZABLE LIPIDS AND NANOPARTICLES COMPRISING SAME | MANA BIO LTD. (IL) | 2024-07-18 | — | — | WO | disclosed |
| CN-118146635-A | Coating composition with polysiloxane modified carbon nanoparticles | NGNT材料科学公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4376837-A1 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | Immunyx Pharma Ltd. (IL) | 2024-06-05 | — | — | EP | disclosed |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-05-16 | — | — | US | disclosed |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | BIOND BIOLOGICS LTD. (IL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024069634-A1 | MICROTUBULE TARGETING AGENTS | Ariel Scientific Innovations Ltd. (IL) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024052923-A1 | IONIZABLE LIPIDS AND COMPOSITIONS COMPRISING SAME | BARCODE NANOTECH LTD. (IL) | 2024-03-14 | — | — | WO | disclosed |
| EP-4326332-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | Biond Biologics Ltd. (IL) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024033917-A1 | GRANULAR COMPOSITIONS COMPRISING A PEPTIDE AND USES THEREOF | TARSIER PHARMA LTD. (IL) | 2024-02-15 | — | — | WO | disclosed |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| US-6133409-A | REACTING A SOLID SUPPORT-BOUND N-ALKYLATED HYDROXAMIC ACID WITH A CARBON-NITROGEN CLEAVING ORGANOMETALLIC COMPUND TO LIBERATE THE PRODUCT KETONE | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6127515-A | Functionalized resin for the synthesis of amides and peptides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000040547-A1 | α-SUBSTITUTION OF UNPROTECTED β-AMINO ESTER COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| EP-0931060-A1 | SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999031491-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999025752-A1 | FUNCTIONALIZED RESIN FOR THE SYNTHESIS OF AMIDES AND PEPTIDES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999000356-A1 | SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | LCAT, CD47, PHOSPHO1 | HTR2C 4752/4885MEN1 762/4885KMT2A 419/4885 |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | ACTB, CHERP, EEA1 | HTR2C 4528/4885MEN1 2434/4885KMT2A 4267/4885 |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | IGF2BP1, IGF2BP2, IGF2BP3 | HTR2C 4559/4885MEN1 855/4885KMT2A 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.